Famciclovir 500 mg Tablets Under Non-Fasting Conditions

NCT00834444 | Completed Phase 1 Results

• 1 other identifier: B044502
• Study Type: interventional
• Target: 36
• Locations: 2 countries
• Sites: 2

Brief Summary

The objective of this study is to compare the relative bioavailability of famciclovir 500 mg tablets (Novopharm Limited) with that of FAMVIR® 500 mg tablets (Novartis) in healthy adult subjects under non-fasting conditions.

Conditions

Healthy

Keywords

Bioequivalence; Healthy Subjects

Outcome Measures

Primary Outcomes (3)

• Cmax = Maximum Observed Concentration.

  Bioequivalence based on Cmax.

  Blood samples collected over a 16 hour period.

• AUC0-t = Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration (Per Participant)

  Bioequivalence based on AUC0-t.

  Blood samples collected over a 16 hour period.

• AUC0-inf = Area Under the Concentration-time Curve From Time Zero to Infinity.

  Bioequivalence based on AUC0-inf.

  Blood samples collected over a 16 hour period.

Study Arms (2)

1

EXPERIMENTAL

Drug: Famciclovir 500 mg Tablets

2

ACTIVE COMPARATOR

Drug: Famvir® 500 mg Tablets

Interventions

Famciclovir 500 mg Tablets DRUG

1 x 500 mg, single-dose fasting

1

Famvir® 500 mg Tablets DRUG

1 x 500 mg, single-dose fasting

2

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• All subjects selected for this study will be at least 18 years of age.
• Each subject shall be given a general physical examination within 28 days of initiation of the study. Such examination includes, but is not limited to, blood pressure, general observations, and history.
• Each female subject will be give a serum pregnancy test as part of the pre-screening process.
• Adequate blood and urine samples should be obtained within 28 days before beginning of the first period and at the end of the trial for clinical laboratory measurements.
• Clinical laboratory measurements will include the following:
• Hematology: hemoglobin, hematocrit, red blood cell count, platelets, and white blood cell count (with differential).
• Clinical Chemistry: creatinine, BUN, glucose, SGOT/AST, SGPT/ALT, bilirubin, and alkaline phosphatase.
• Urine Analysis: pH, specific gravity, protein, glucose, ketones, bilirubin, occult blood, and cells.
• HIV Screen: pre-study only.
• Hepatitis-B, C Screen: pre-study only.
• Drugs of Abuse Screen: pre-study and at check-in each study period.
• Electrocardiograms of all participating subjects will be recorded before initiation of the study and filed with each subject's case report forms.

You may not qualify if:

• Subjects with a history of alcoholism or drug addiction (during past 2 years), or serious gastrointestinal, renal, hepatic, or cardiovascular disease, tuberculosis, epilepsy, asthma (during past 5 years), diabetes, psychosis or glaucoma will not be eligible for this study.
• Subjects whose clinical laboratory test values are outside the normal range may be retested at the discretion of the clinical investigator. If the clinical values are outside the range on retesting, the subject will not be eligible to participate in the study unless the clinical investigator deems the result to not be significant.
• Subjects who have a history of allergic responses to the class of drug being tested should be excluded form the study.
• All subjects will have urine samples assayed for the presence of drugs of abuse as part of the clinical laboratory screening procedures and at each check-in. Subjects found to have urine concentrations of any of the tested drugs will not be allowed to participate.
• Subjects should not have donated blood and/or plasma for at least thirty (30) days prior to the first dosing of the study.
• Subjects who have taken any investigational drug within thirty (30) days prior to the first dosing of the study will not be allowed to participate.
• Female subjects who are pregnant, breast-feeding, or who are likely to become pregnant during the study will not be allowed to participate. Female subjects of child bearing potential must either abstain from sexual intercourse or use a reliable barrier method (e.g. condom, IUD) of contraception during the course of the study (first dosing until last blood collection) or they will not be allowed to participate. Subjects who have used implanted or injected hormonal contraceptives anytime during the 6 months prior to study dosing, or used oral hormonal contraceptives within 14 days before dosing will not be allowed to participate.
• All female subjects will be screened for pregnancy at check-in each study period. Subjects with positive or inconclusive results will be withdrawn from the study.

Sponsors & Collaborators

• Teva Pharmaceuticals USA: lead

Study Sites (2)

Gateway Medical Research, Inc.

Saint Charles, Missouri, 63301, United States

Location

Ba Research Co.

Toronto, Ontario, M1P2X4, Canada

Location

MeSH Terms

Interventions

Famciclovir

Intervention Hierarchy (Ancestors)

Adenine; Purines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds

Results Point of Contact

• Title: Manager, Biopharmaceutics
• Organization: Manager, Biopharmaceutics

clinicaltrialqueries@tevausa.com

1-866-384-5525

Study Officials

• Irwin Plisco, M.D.

  Cetero Research, San Antonio

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: January 30, 2009
• First Posted: February 3, 2009
• Study Start: August 1, 2004
• Primary Completion: September 1, 2004
• Study Completion: September 1, 2004
• Last Updated: August 20, 2024
• Results First Posted: August 4, 2009

Record last verified: 2024-08

Locations

CA (1); US (1)